Bausch Lomb Operating Income Over Time
| BLCO Stock | USD 16.85 0.15 0.90% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bausch Lomb Performance and Bausch Lomb Correlation. Will Health Care Equipment & Supplies sector continue expanding? Could Bausch diversify its offerings? Factors like these will boost the valuation of Bausch Lomb. Projected growth potential of Bausch fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bausch Lomb data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.89) | Earnings Share (0.85) | Revenue Per Share | Quarterly Revenue Growth 0.071 | Return On Assets |
Understanding Bausch Lomb Corp requires distinguishing between market price and book value, where the latter reflects Bausch's accounting equity. The concept of intrinsic value—what Bausch Lomb's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Bausch Lomb's price substantially above or below its fundamental value.
It's important to distinguish between Bausch Lomb's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bausch Lomb should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Bausch Lomb's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Bausch Lomb Corp and related stocks such as Teleflex Incorporated, Merit Medical Systems, and Vaxcyte Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TFX | 20.6 M | 233.2 M | (97.4 M) | 233.3 M | 284.9 M | 315.9 M | 319.5 M | 372.3 M | 321.7 M | 427.3 M | 423.1 M | 628.1 M | 499.7 M | 506.3 M | 151 M | 173.7 M | 278.1 M |
| MMSI | (400 K) | 33.2 M | 29.6 M | 27.8 M | 40.2 M | 37.5 M | 34.9 M | 33.1 M | 58.6 M | 15.4 M | (1.6 M) | 60.9 M | 87.6 M | 123.9 M | 155.7 M | 179 M | 188 M |
| PCVX | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (35.5 M) | (54.2 M) | (89.6 M) | (103.7 M) | (232.3 M) | (468 M) | (569.5 M) | (512.6 M) | (487 M) |
| CRSP | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (25.7 M) | (68.1 M) | (64.6 M) | (158.9 M) | 46.7 M | (354.4 M) | 373.5 M | (673.2 M) | (222.5 M) | (466.6 M) | (419.9 M) | (398.9 M) |
| ARWR | (158.6 K) | (21.1 M) | (24.6 M) | (53.3 M) | (96 M) | (81.7 M) | (37 M) | (55.9 M) | 61.2 M | (93.2 M) | (149 M) | (178.5 M) | (205 M) | (601.1 M) | 98.3 M | 88.5 M | 92.9 M |
| PTCT | 30.6 M | 30.6 M | (26.8 M) | (45.4 M) | (99.4 M) | (167.1 M) | (132.1 M) | (64.3 M) | (115.7 M) | (241.2 M) | (431.8 M) | (374.4 M) | (447.4 M) | (439.5 M) | (302.6 M) | (272.3 M) | (285.9 M) |
| GKOS | (22.1 M) | (22.1 M) | (22.1 M) | (14.2 M) | (13.2 M) | (10.3 M) | 4.2 M | (2.3 M) | (13 M) | (50.3 M) | (123.6 M) | (32.9 M) | (82.3 M) | (128.7 M) | (122.4 M) | (110.1 M) | (104.6 M) |
| ACLX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (18 M) | (32.1 M) | (65 M) | (191.3 M) | (89.9 M) | (137.6 M) | (123.8 M) | (130 M) |
| TGTX | (3.8 M) | (882 K) | (26.9 M) | (23 M) | (55.7 M) | (63.2 M) | (79 M) | (118.7 M) | (174.4 M) | (169.1 M) | (273.6 M) | (344.8 M) | (218.3 M) | 20.6 M | 41.9 M | 37.7 M | 39.6 M |
| OSCR | (259.4 M) | (259.4 M) | (259.4 M) | (259.4 M) | (259.4 M) | (259.4 M) | (259.4 M) | (259.4 M) | (259.4 M) | (259.4 M) | (405.8 M) | (570.6 M) | (610.1 M) | (235.6 M) | 33.4 M | 38.4 M | 40.4 M |
Bausch Lomb Corp and related stocks such as Teleflex Incorporated, Merit Medical Systems, and Vaxcyte Operating Income description
Operating Income is the amount of profit realized from Bausch Lomb Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Bausch Lomb Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Bausch Lomb Corp | BLCO |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 520 Applewood Crescent, |
| Exchange | New York Stock Exchange |
USD 16.85
Check out Bausch Lomb Performance and Bausch Lomb Correlation. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Bausch Lomb technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.